Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML
07 juin 2021 08h30 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today...
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
04 juin 2021 09h00 HE
|
Cullinan Oncology, Inc.
CLN-081 Continues to Demonstrate Acceptable Overall Safety and Tolerability, With Encouraging GI Toxicity ProfileAs of the Data Cutoff, No Grade 3 TRAE Diarrhea at Doses Below 150mg BID; No Grade 3...
Cullinan Oncology Announces Management Transition
21 mai 2021 08h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today...
Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021
19 mai 2021 17h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today...
Cullinan Oncology Reports First Quarter 2021 Financial Results
14 mai 2021 06h30 HE
|
Cullinan Oncology, Inc.
Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations Cash, cash equivalents and investments of...
Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference
07 avr. 2021 10h08 HE
|
Cullinan Management, Inc.
CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company’s Chief Financial Officer, Jeff Trigilio, will present at...
Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights
30 mars 2021 06h15 HE
|
Cullinan Management, Inc.
Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan...
Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference
02 mars 2021 09h48 HE
|
Cullinan Management, Inc.
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Management, Inc. Announces Business Update
22 févr. 2021 07h30 HE
|
Cullinan Management, Inc.
February 22, 2021 Enrollment expansion in CLN-081 NSCLC EGFRex20ins Phase 1/2a trialCullinan withdraws IND application for CLN-049 in Relapsed/Refractory AMLCLN-619 IND submission planned for the...
Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12 janv. 2021 21h43 HE
|
Cullinan Management, Inc.
CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and...